logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Niharika B. Mettu

duke university
H指数:13
被引数:811

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A window-of-opportunity trial using neoadjuvant hepatic artery chemotherapy for patients with localized pancreas cancer: Interim analysis of safety and feasibility
CANCER RESEARCH
IF16.6
2024-09-150
PRE
Agritelley, Ethan S.; Kanu, Elishama N.; Bao, Jiayin; Fletcher, Ashley A.; Skinner, Holly; Molvin, Adi; Murray, Stacy; Kim, Charles Y.; Cline, Brendan; Mastria, Eric; Johnson, David Y.; DeVito, Nicholas C.; Blobe, Gerard C.; Abbruzzese, James L.; Crosby, Erika J.; Martin, Allison; Mettu, Niharika B.; Allen, Peter J.; Nussbaum, Daniel P.
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2024-05-062
OAAI
Fontana, Elisa; Rosen, Ezra; Lee, Elizabeth K.; Hojgaard, Martin; Mettu, Niharika B.; Lheureux, Stephanie; Carneiro, Benedito A.; Cote, Gregory M.; Carter, Louise; Plummer, Ruth; Mahalingam, Devalingam; Fretland, Adrian J.; Schonhoft, Joseph D.; Silverman, Ian M.; Wainszelbaum, Marisa; Xu, Yi; Ulanet, Danielle; Koehler, Maria; Yap, Timothy A.
NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Khan, Khurum; Mukherjee, Uma; Schlechter, Benjamin L.; Ciombor, Kristen K.; Skolariki, Aglaia; Coveler, Andrew L.; Graham, Janet S.; Peters, Mary Linton; Cohen, Stacey A.; Mettu, Niharika; Marijon, Helene; Cosgrove, David; McKissock, Fiona G.; Oelmann, Elisabeth; Bloss, Jeffrey D.; Blagden, Sarah P.; de Gramont, Aimery; Berlin, Jordan; Evans, T. R. Jeffry
Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Rosen, Ezra; Yap, Timothy A.; Fontana, Elisa; Lee, Elizabeth K.; Mahalingam, Devalingam; Hojgaard, Martin; Mettu, Niharika B.; Cote, Gregory M.; Plummer, Ruth; Silverman, Ian M.; Schonhoft, Joseph D.; Bacque, Emeline; Fretland, Adrian J.; Gomez, Gabriela; Ulanet, Danielle; Fei, Kezhen; Yang, Julia; Koehler, Maria; Roulston, Anne; Li, Li; Zimmermann, Michel; Carneiro, Benedito A.; Lheureux, Stephanie
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
NATURE MEDICINE
IF50
2023-06-0530
OAAI
Yap, Timothy A. A.; Fontana, Elisa; Lee, Elizabeth K.; Spigel, David R. R.; Hojgaard, Martin; Lheureux, Stephanie; Mettu, Niharika B. B.; Carneiro, Benedito A. A.; Carter, Louise; Plummer, Ruth; Cote, Gregory M. M.; Meric-Bernstam, Funda; O'Connell, Joseph; Schonhoft, Joseph D. D.; Wainszelbaum, Marisa; Fretland, Adrian J. J.; Manley, Peter; Xu, Yi; Ulanet, Danielle; Rimkunas, Victoria; Zinda, Mike; Koehler, Maria; Silverman, Ian M. M.; Reis-Filho, Jorge S. S.; Rosen, Ezra
Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations
CANCER RESEARCH
IF16.6
2023-04-140
PRE
Yap, Timothy A.; Yadav, Siddhartha; Herzberg, Benjamin; Carneiro, Benedito A.; Fontana, Elisa; Hojgaard, Martin; Pishvaian, Michael J.; Plummer, Ruth; Werner, Theresa L.; Sahai, Vaibhav; Lheureux, Stephanie; Lee, Elizabeth K.; Mettu, Niharika B.; Cote, Gregory M.; Schonhoft, Joseph D.; Rimkunas, Victoria; Silverman, Ian M.; Wainszelbaum, Marisa; Peltz, Gerson; Fretland, Adrian J.; Fei, Kezhen; Ulanet, Danielle; Kim, Insil; Koehler, Maria; Rosen, Ezra; Cecchini, Michael
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

布鲁顿酪氨酸激酶抑制剂acalabrutinib单独或联合pembrolizumab治疗晚期胰腺癌患者的随机II期研究

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2020-02-2871
OAAI
Overman, Michael; Javle, Milind; Davis, Richard E.; Vats, Pankaj; Kumar-Sinha, Chandan; Xiao, Lianchun; Mettu, Niharika B.; Parra, Edwin R.; Benson, Al B.; Lopez, Charles D.; Munugalavadla, Veerendra; Patel, Priti; Tao, Lin; Neelapu, Sattva; Maitra, Anirban
FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
MOLECULAR CANCER THERAPEUTICS
IF5.5
2019-12-019
PRE
Subbiah, Vivek; Barve, Minal; Iannotti, Nicholas O.; Gutierrez, Martin; Smith, David C.; Roychowdhury, Sameek; Papadopoulos, Kyriakos P.; Mettu, Niharika; Edenfield, William J.; Morgensztern, Daniel; Feliz, Luis; Lihou, Christine; Zhen, Huiling; Saleh, Mansoor

研究方向

暂未获取到该数据
E
Ezra Y. Rosen
H 指数:18论文数:174被引数:3,178
R
Ruth Plummer
H 指数:59论文数:604被引数:1.3万
M
Martin Højgaard
H 指数:9论文数:59被引数:548
T
Timothy A. Yap
H 指数:77论文数:1,361被引数:2.6万
D
Danielle Ulanet
H 指数:14论文数:70被引数:1,609
E
Elisa Fontana
H 指数:20论文数:216被引数:1,874
S
Stéphanie Lheureux
H 指数:38论文数:473被引数:7,789
B
Benedito A. Carneiro
H 指数:40论文数:511被引数:9,176
J
Joseph D. Schonhoft
H 指数:22论文数:123被引数:1,547
A
Adrian J. Fretland
H 指数:28论文数:92被引数:3,038